Neurotransmitter antagonism in management of irritable bowel syndrome

Recently developed therapies for irritable bowel syndrome (IBS) have focused on modulation of neurotransmitters in the "brain-gut" axis. A study has shown some beneficial effect of alosetron, the drug has not yet been compared with existing pharmacological or psychological therapies.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet (British edition) 2000-03, Vol.355 (9209), p.1030-1031
1. Verfasser:	Lembo, Tony
Format:	Artikel
Sprache:	eng
Schlagworte:	Carbolines - therapeutic use Colonic Diseases, Functional - drug therapy Colonic Diseases, Functional - physiopathology Digestive system Humans Medical disorders Medical research Serotonin - physiology Serotonin Antagonists - therapeutic use Therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Recently developed therapies for irritable bowel syndrome (IBS) have focused on modulation of neurotransmitters in the "brain-gut" axis. A study has shown some beneficial effect of alosetron, the drug has not yet been compared with existing pharmacological or psychological therapies.
ISSN:	0140-6736 1474-547X
DOI:	10.1016/S0140-6736(00)02028-6